Phase II study of 9-10 anthracene-dicarboxaldehyde bis(4,5-dihydro-1H-imidazol-2-yl) hydrazone dihydrochloride (CL216,942; ADAH) in patients with advanced colorectal carcinoma.
A phase II study of ADAH was conducted in thirty patients with biopsy-prove metastatic or recurrent colorectal carcinoma in order to define its benefits and toxicity. Doses were adjusted by leukocyte nadirs. No patients met the criteria for complete or partial response.
D000230:Adenocarcinoma / Q000188:drug therapy*; D000368:Aged; D000873:Anthracenes / Q000009:adverse effects / Q000627:therapeutic use; D000903:Antibiotics, Antineoplastic / Q000009:adverse effects / Q000627:therapeutic use*; D003110:Colonic Neoplasms / Q000188:drug therapy*; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007958:Leukocyte Count; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009364:Neoplasm Recurrence, Local; D012004:Rectal Neoplasms / Q000188:drug therapy*
D000873:Anthracenes; D000903:Antibiotics, Antineoplastic; C031404:bisantrene